Mar
12
2020
On demand

Ensuring source material consistency and continuity for commercialization of advanced therapies

A critical aspect to ensuring patient access to cell and gene therapies (CGT) and continued growth of the industry is having a proper awareness for managing the source material quality and supply chain continuity. The combination of rapid growth, individual product and process complexity, and limited industry-specific guidance or awareness presents ongoing challenges for transitioning from development to clinical and commercial manufacturing scale. For allogeneic therapies, having access to consistent and reliable donors and high quality, GMP-compliant starting material, coupled with the ability to consistently deliver this clinical source material to the required point of use, will be key to long-term success.

Three diverse stakeholders share their experience and insights to help you troubleshoot your own cell therapy raw and starting materials strategy:

  • Dominic Clarke of HemaCare introduces the key considerations for starting material sourcing, including addressing translational and scale-up challenges.
  • Christopher Good of Biocair highlights regional and regulatory logistics requirements, and the major considerations for shipping clinical/GMP starting materials
  • Amy Shaw of Beam Therapeutics provides practical guidance relating to the critical role of both material sourcing and logistics in the effective development of novel advanced therapies, drawing on Beam’s own experiences with the development of its autologous and allogeneic product candidates.

Improve your knowledge of:

  • The importance of defining source material requirements for translation of allogeneic advanced therapies
  • The benefits of a reliable & recallable donor network for consistent source material access
  • The critical requirements for obtaining GMP-compliant source materials necessary for commercial manufacture
  • How to navigate the critical aspects in handling, monitoring, and delivering temperature sensitive source materials
  • The importance of early planning, coordination, and communication with all stakeholders

Dominic Clarke
Global Head of Cell Therapy, HemaCare Corporation
Amy Shaw
Lead, Cell Therapies Engineering & Automation Development at Takeda Pharmaceutical Company Limited
Christopher Good
Director, Cell & Gene Therapy Logistics at Biocair International Limited

SPEAKERS

Dominic Clarke
Global Head of Cell Therapy, HemaCare Corporation
Amy Shaw
Lead, Cell Therapies Engineering & Automation Development at Takeda Pharmaceutical Company Limited
Christopher Good
Director, Cell & Gene Therapy Logistics at Biocair International Limited

You might also like

Thinking translational: Things to consider in CAR T cell research workflows

S Rösch, PhD
Saskia Rösch, PhD
Saskia Rösch, PhD
Global Product Manager at Miltenyi Biotec
22 Jun 2022
34
Days
23
Hrs
36
Min
Register

Optimizing mRNA purification conditions by using a Design of Experiments...

J England
Jenny England
Jenny England
Application Scientist and Innovation Leader at Thermo Fisher Scientific
14 Jun 2022
26
Days
23
Hrs
36
Min
Register

Monitoring of circulating CAR T cells

A Graband,
D Hünecke,
D Bremm
Annika Graband
Annika Graband
Product Manager, Cell Analysis Reagents at Miltenyi Biotec
Dr. Sabine Hünecke
Dr. Sabine Hünecke
Head of Laboratory, Stem Cell Transplantation and Immunotherapy at University Hospital Frankfurt
Dr. Melanie Bremm
Dr. Melanie Bremm
Deputy Head of Laboratory, Stem Cell Transplantation and Immunotherapy at University Hospital Frankfurt
31 May 2022
12
Days
23
Hrs
36
Min
Register

Improving T cell therapy manufacturing processes with automation and...

E Zynda, PhD
Evan Zynda, PhD
Evan Zynda, PhD
Staff Scientist, Cell Biology at Thermo Fisher Scientific
26 May 2022
7
Days
23
Hrs
36
Min
Register

Streamlined workflow solutions for cell and gene therapy analytics

A Graband
Annika Graband
Annika Graband
Product Manager, Cell Analysis Reagents at Miltenyi Biotec
24 May 2022
5
Days
23
Hrs
36
Min
Register